- (Abstract #1698): Monday, April 7, 2014, 8:00 a.m. – 12:00 p.m. PT, “Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells,” T. Uenaka et. al., Hall A-E, Poster Section 29, San Diego Convention Center.
- (Abstract #4765): Tuesday, April 8, 2014, 3:05 p.m. – 3:20 p.m. PT, “Drug synergies observed for antibody and toxin components of SAR3419 ADC contribute to overall conjugate efficacy and can be combination drug or tumor cell line dependent,” R. J. Rickles, et. al., Session: Novel Biologics as Targeted Cancer Therapy, Room 5, San Diego Convention Center.
(c) 2014 Zalicus Inc. All rights reserved.